Mechanism of Tianma Gouteng Decoction in the treatment of Parkinson's disease based on network pharmacology and molecular docking

Objective: To explore the pharmacological mechanism and molecular targets of Tianma Gouteng Decoction (TMGTD) in the treatment of Parkinson's disease (PD). Methods: We applied network pharmacology to screen the active components of TMGTD and predict target genes in multiple Chinese herbal medicine databases and com-pound databases, and built a drug-ingredient-target network. Then, we used the CytoHubba plug-in to filter out the core components of TMGTD according to the order of degree value. We screened PD-related pathogenic targets in the DrugBank, Genecard and OMIM databases from high to low in Betweenness Centrality (BC) value and Closeness Centrality (CC) value. Subsequently, we determined the intersection target of TMGTD and PD by Venn diagram and performed protein-protein interaction (PPI) analysis, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis on core molecules and intersection targets. Finally, molecular dock -ing was performed to verify the binding of the top three core molecules of TMGTD with the top three core targets of PD. Results: The core components of TMGTD are quercetin, kaempferol and palmitic acid. The main targets of TMGTD in the treatment of PD are ALB, GAPDH and AKT1. GO analysis and KEGG analysis showed that the biological process of TMGTD in the treatment of PD is closely related to the activities of neurotransmitter receptors, G protein-coupled receptors and dopamine neurotransmitter receptors. TMGTD possesses therapeutic effects on PD mainly through the PI3K-Akt signaling pathway and MAPK signaling pathway. Molecular docking shows the high affinity of the quercetin, kaempferol and palmitic acid with PD core targets. Conclusion: TMGTD plays a pivotal role in the treat-ment of PD through multiple components, multiple targets and multiple pathways. The results provide a research direction for the subsequent exploration of the mechanism of TMGTD in PD treatment.